New data from a phase 1b/2 clinical trial shows that a specific protein called CD47 can help predict how well the investigational drug evorpacept works for patients with metastatic breast cancer, ALX ...

CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...

Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – ...

The Phase Ib/II trial assessed evorpacept plus zanidatamab in previously treated, metastatic HER2-expressing cancers.

Immunotherapy has transformed cancer care, offering a way to harness the body’s own immune system to fight tumors. But even with these advances, many patients still don’t respond. One major barrier to ...

The company reiterated that the ASPEN-Breast Phase II trial is "on track to dose its first patient this quarter," with interim data expected in Q3 2026. ALX2004 initial safety data is expected in the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company raised hundreds of ...